The PD-1/PD-L1 pathway is a mechanism that cancer cells use to evade the immune system. Pembrolizumab binds to the PD-1 receptor, preventing interaction with its ligands (PD-L1 and PD-L2), and thus reactivates the T-cells to attack cancer cells. This mechanism is particularly effective in cancers that express high levels of PD-L1.
